File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Expression of inhibitory receptors in natural killer (CD3-CD56+) cells and CD3+CD56+ cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma

TitleExpression of inhibitory receptors in natural killer (CD3-CD56+) cells and CD3+CD56+ cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma
Authors
Issue Date2001
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/yclim
Citation
Clinical Immunology, 2001, v. 101 n. 3, p. 264-269 How to Cite?
AbstractThe cytolytic responses of NK (CD3-CD56+) and CD3+CD56+ cells are inhibited by the engagement of the killer inhibitory receptors (p58.1, p58.2, and CD94) with respective ligands on the target cell. The expression of these receptors in peripheral blood lymphocytes (PBLs) (n = 18) and tumor infiltrating lymphocytes (TILs) (n = 7) was examined in patients with primary hepatocellular carcinoma (HCC). There were no differences in the expression of the three inhibitory receptors by both NK and CD3+CD56+ PBLs in patients with HCC compared to that of control NK and CD3+CD56+ PBLs, respectively (all P = NS). However, the expression of p58.1 by NK TILs and by CD3+CD56+ TILs in patients with HCC was significantly decreased compared to that of hepatic lymphocytes of the control subjects (8.9% vs 37.85%, P = 0.047; 4.1% vs 25.2%, P = 0.049, respectively). The expression of p58.2 by CD3+CD56+ TILs and CD94 by NK TILs was also decreased compared to that of hepatic lymphocytes of the control subjects (16.9% vs 73.1%, P = 0.047; 21% vs 49.95%, P = 0.037, respectively). These changes were limited to hepatic TILs, and this observation may reflect an adaptive anti-tumor phenomenon occurring in the microenvironment of HCC. © 2001 Elsevier Science.
Persistent Identifierhttp://hdl.handle.net/10722/162518
ISSN
2015 Impact Factor: 4.034
2015 SCImago Journal Rankings: 1.848
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_US
dc.contributor.authorNorris, Sen_US
dc.date.accessioned2012-09-05T05:20:42Z-
dc.date.available2012-09-05T05:20:42Z-
dc.date.issued2001en_US
dc.identifier.citationClinical Immunology, 2001, v. 101 n. 3, p. 264-269en_US
dc.identifier.issn1521-6616en_US
dc.identifier.urihttp://hdl.handle.net/10722/162518-
dc.description.abstractThe cytolytic responses of NK (CD3-CD56+) and CD3+CD56+ cells are inhibited by the engagement of the killer inhibitory receptors (p58.1, p58.2, and CD94) with respective ligands on the target cell. The expression of these receptors in peripheral blood lymphocytes (PBLs) (n = 18) and tumor infiltrating lymphocytes (TILs) (n = 7) was examined in patients with primary hepatocellular carcinoma (HCC). There were no differences in the expression of the three inhibitory receptors by both NK and CD3+CD56+ PBLs in patients with HCC compared to that of control NK and CD3+CD56+ PBLs, respectively (all P = NS). However, the expression of p58.1 by NK TILs and by CD3+CD56+ TILs in patients with HCC was significantly decreased compared to that of hepatic lymphocytes of the control subjects (8.9% vs 37.85%, P = 0.047; 4.1% vs 25.2%, P = 0.049, respectively). The expression of p58.2 by CD3+CD56+ TILs and CD94 by NK TILs was also decreased compared to that of hepatic lymphocytes of the control subjects (16.9% vs 73.1%, P = 0.047; 21% vs 49.95%, P = 0.037, respectively). These changes were limited to hepatic TILs, and this observation may reflect an adaptive anti-tumor phenomenon occurring in the microenvironment of HCC. © 2001 Elsevier Science.en_US
dc.languageengen_US
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/yclimen_US
dc.relation.ispartofClinical Immunologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntigens, Cd3 - Immunologyen_US
dc.subject.meshAntigens, Cd56 - Immunologyen_US
dc.subject.meshB-Lymphocyte Subsets - Immunology - Pathologyen_US
dc.subject.meshCarcinoma, Hepatocellular - Immunology - Pathologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshKiller Cells, Natural - Immunology - Pathologyen_US
dc.subject.meshLiver Neoplasms - Immunology - Pathologyen_US
dc.subject.meshLymphocytes, Tumor-Infiltrating - Immunology - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshReceptors, Immunologic - Biosynthesis - Immunologyen_US
dc.subject.meshReceptors, Kiren_US
dc.subject.meshReceptors, Kir2dl3en_US
dc.titleExpression of inhibitory receptors in natural killer (CD3-CD56+) cells and CD3+CD56+ cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1006/clim.2001.5110en_US
dc.identifier.pmid11726217-
dc.identifier.scopuseid_2-s2.0-0035207022en_US
dc.identifier.hkuros131149-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035207022&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume101en_US
dc.identifier.issue3en_US
dc.identifier.spage264en_US
dc.identifier.epage269en_US
dc.identifier.isiWOS:000172728500002-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US
dc.identifier.scopusauthoridNorris, S=7103213449en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats